Logo image of GRAL

GRAIL INC (GRAL) Stock Fundamental Analysis

NASDAQ:GRAL - Nasdaq - US3847471014 - Common Stock - Currency: USD

40.4486  -0.28 (-0.69%)

Fundamental Rating

4

Overall GRAL gets a fundamental rating of 4 out of 10. We evaluated GRAL against 558 industry peers in the Biotechnology industry. While GRAL has a great health rating, there are worries on its profitability. GRAL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GRAL had negative earnings in the past year.
GRAL had a negative operating cash flow in the past year.
GRAL had negative earnings in each of the past 5 years.
GRAL had a negative operating cash flow in each of the past 5 years.
GRAL Yearly Net Income VS EBIT VS OCF VS FCFGRAL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2021 2022 2023 2024 -1B -2B -3B -4B -5B

1.2 Ratios

Looking at the Return On Assets, with a value of -67.23%, GRAL is doing worse than 62.37% of the companies in the same industry.
GRAL has a Return On Equity of -79.31%. This is comparable to the rest of the industry: GRAL outperforms 51.43% of its industry peers.
Industry RankSector Rank
ROA -67.23%
ROE -79.31%
ROIC N/A
ROA(3y)-71.58%
ROA(5y)N/A
ROE(3y)-79.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRAL Yearly ROA, ROE, ROICGRAL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

With a decent Gross Margin value of 44.26%, GRAL is doing good in the industry, outperforming 75.63% of the companies in the same industry.
In the last couple of years the Gross Margin of GRAL has grown nicely.
GRAL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.32%
GM growth 5YN/A
GRAL Yearly Profit, Operating, Gross MarginsGRAL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

GRAL does not have a ROIC to compare to the WACC, probably because it is not profitable.
GRAL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GRAL has less shares outstanding
There is no outstanding debt for GRAL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GRAL Yearly Shares OutstandingGRAL Yearly Shares OutstandingYearly Shares Outstanding 2019 2021 2022 2023 2024 20M 40M 60M 80M 100M
GRAL Yearly Total Debt VS Total AssetsGRAL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

Based on the Altman-Z score of -3.33, we must say that GRAL is in the distress zone and has some risk of bankruptcy.
GRAL has a Altman-Z score (-3.33) which is in line with its industry peers.
There is no outstanding debt for GRAL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.33
ROIC/WACCN/A
WACC9.68%
GRAL Yearly LT Debt VS Equity VS FCFGRAL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 9.71 indicates that GRAL has no problem at all paying its short term obligations.
GRAL has a better Current ratio (9.71) than 77.78% of its industry peers.
GRAL has a Quick Ratio of 9.71. This indicates that GRAL is financially healthy and has no problem in meeting its short term obligations.
GRAL has a Quick ratio of 9.71. This is in the better half of the industry: GRAL outperforms 77.78% of its industry peers.
Industry RankSector Rank
Current Ratio 9.71
Quick Ratio 9.71
GRAL Yearly Current Assets VS Current LiabilitesGRAL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

GRAL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.10%.
The Revenue has grown by 34.90% in the past year. This is a very strong growth!
GRAL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 104.84% yearly.
EPS 1Y (TTM)-15.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.45%
Revenue 1Y (TTM)34.9%
Revenue growth 3Y104.84%
Revenue growth 5YN/A
Sales Q2Q%19.15%

3.2 Future

GRAL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.11% yearly.
GRAL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.19% yearly.
EPS Next Y79.08%
EPS Next 2Y34.07%
EPS Next 3Y22.11%
EPS Next 5YN/A
Revenue Next Year19.97%
Revenue Next 2Y19.07%
Revenue Next 3Y18.19%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GRAL Yearly Revenue VS EstimatesGRAL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
GRAL Yearly EPS VS EstimatesGRAL Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GRAL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GRAL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRAL Price Earnings VS Forward Price EarningsGRAL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRAL Per share dataGRAL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60 -60

4.3 Compensation for Growth

A more expensive valuation may be justified as GRAL's earnings are expected to grow with 22.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.07%
EPS Next 3Y22.11%

More info and screens

0

5. Dividend

5.1 Amount

GRAL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRAIL INC

NASDAQ:GRAL (7/14/2025, 12:02:03 PM)

40.4486

-0.28 (-0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11
Inst Owners66.5%
Inst Owner Change0%
Ins Owners1.41%
Ins Owner Change3.56%
Market Cap1.45B
Analysts76
Price Target32.13 (-20.57%)
Short Float %19.23%
Short Ratio3.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.28%
Min EPS beat(2)25.93%
Max EPS beat(2)42.64%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.16%
Min Revenue beat(2)-11.33%
Max Revenue beat(2)9.02%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)57.5%
EPS NQ rev (1m)9.33%
EPS NQ rev (3m)8.94%
EPS NY rev (1m)12.31%
EPS NY rev (3m)10.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.98%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)-3.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.13
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 3.37
EV/EBITDA N/A
EPS(TTM)-60.98
EYN/A
EPS(NY)-13.78
Fwd EYN/A
FCF(TTM)-13
FCFYN/A
OCF(TTM)-12.92
OCFYN/A
SpS3.63
BVpS67.1
TBVpS11.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.23%
ROE -79.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.26%
FCFM N/A
ROA(3y)-71.58%
ROA(5y)N/A
ROE(3y)-79.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.32%
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.73%
Cap/Sales 2.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.71
Quick Ratio 9.71
Altman-Z -3.33
F-Score5
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)8.73%
Cap/Depr(5y)N/A
Cap/Sales(3y)19.71%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.45%
EPS Next Y79.08%
EPS Next 2Y34.07%
EPS Next 3Y22.11%
EPS Next 5YN/A
Revenue 1Y (TTM)34.9%
Revenue growth 3Y104.84%
Revenue growth 5YN/A
Sales Q2Q%19.15%
Revenue Next Year19.97%
Revenue Next 2Y19.07%
Revenue Next 3Y18.19%
Revenue Next 5YN/A
EBIT growth 1Y3.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year83.4%
EBIT Next 3Y22.6%
EBIT Next 5YN/A
FCF growth 1Y4.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.13%
OCF growth 3YN/A
OCF growth 5YN/A